The role of non-HLA single nucleotide polymorphisms in multiple sclerosis susceptibility

Journal of Neuroimmunology

Volumn 229, Issue 1-2, 2010, Pages 5-15

  Bahreini, Seyed Amir ^a   Jabalameli, M Reza ^a   Saadatnia, Mohammad ^b   Zahednasab, Hamid ^a  

^a UNIVERSITY OF ISFAHAN   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Genome wide association study; Multiple sclerosis; Non HLA genes; Single nucleotide polymorphism

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; CASPASE RECRUITMENT DOMAIN PROTEIN 4; CD4 ANTIGEN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLYPICAN; GLYPICAN 1; GLYPICAN 3; HLA DQB1 ANTIGEN; HLA DR ANTIGEN; HLA DR15 ANTIGEN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; INTERFERON REGULATORY FACTOR 5; INTERLEUKIN 1BETA; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4 RECEPTOR; INTERLEUKIN 7 RECEPTOR ALPHA; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; MAJOR HISTOCOMPATIBILITY ANTIGEN; PROTEIN KINASE C ALPHA; RETINOIC ACID INDUCIBLE PROTEIN I; RYANODINE RECEPTOR 2; TOLL LIKE RECEPTOR 1; UNCOUPLING PROTEIN 2;

AFRICAN AMERICAN; AUSTRALIA; BELGIUM; CANADA; CAUCASIAN; EUROPE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; HERITABILITY; HISPANIC; HUMAN; MULTIPLE SCLEROSIS; NETHERLANDS; NORWAY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SWEDEN; UNITED KINGDOM; UNITED STATES;

ETHNIC GROUPS; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MULTIPLE SCLEROSIS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 78650309500     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2010.08.002     Document Type: Review

References (121)

1. Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. Nat. Genet. 2009, 41:824-828. (ANZgene) TAaNZMSGC.
2. The expanding genetic overlap between multiple sclerosis and type I diabetes. Genes Immun. 2009, 10:11-14. (IMSGC) IMSGC.
3. Akkad D.A., Hoffjan S., Petrasch-Parwez E., Beygo J., Gold R., Epplen J.T. Variation in the IL7RA and IL2RA genes in German multiple sclerosis patients. J. Autoimmun. 2009, 32:110-115.
4. Aktan F. iNOS-mediated nitric oxide production and its regulation. Life Sci. 2004, 75:639-653.
5. Alcina A., Fedetz M., Ndagire D., Fernandez O., Leyva L., Guerrero M., et al. The T244I variant of the interleukin-7 receptor-alpha gene and multiple sclerosis. Tissue Antigens 2008, 72:158-161.
6. Alcina A., Fedetz M., Ndagire D., Fernandez O., Leyva L., Guerrero M., et al. IL2RA/CD25 gene polymorphisms: uneven association with multiple sclerosis (MS) and type 1 diabetes (T1D). PLoS ONE 2009, 4:e4137.
7. Alcina A., Fernandez O., Gonzalez J.R., Catala-Rabasa A., Fedetz M., Ndagire D., et al. Tag-SNP analysis of the GFI1-EVI5-RPL5-FAM69 risk locus for multiple sclerosis. Eur. J. Hum. Genet. 2010, 18:827-831.
8. Allen I.V. The pathology of multiple sclerosis-fact, fiction and hypothesis. Neuropathol. Appl. Neurobiol. 1981, 7:169-182.
9. Aulchenko Y.S., Hoppenbrouwers I.A., Ramagopalan S.V., Broer L., Jafari N., Hillert J., et al. Genetic variation in the KIF1B locus influences susceptibility to multiple sclerosis. Nat. Genet. 2008, 40:1402-1403.
10. Banchereau J., Bazan F., Blanchard D., Briere F., Galizzi J.P., van Kooten C., et al. The CD40 antigen and its ligand. Annu. Rev. Immunol. 1994, 12:881-922.
11. Baranzini S.E., Wang J., Gibson R.A., Galwey N., Naegelin Y., Barkhof F., et al. Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum. Mol. Genet. 2009, 18:767-778.
12. Barcellos L.F., Begovich A.B., Reynolds R.L., Caillier S.J., Brassat D., Schmidt S., et al. Linkage and association with the NOS2A locus on chromosome 17q11 in multiple sclerosis. Ann. Neurol. 2004, 55:793-800.
13. Barnes B.J., Kellum M.J., Field A.E., Pitha P.M. Multiple regulatory domains of IRF-5 control activation, cellular localization, and induction of chemokines that mediate recruitment of T lymphocytes. Mol. Cell. Biol. 2002, 22:5721-5740.
14. Barton A., Woolmore J.A., Ward D., Eyre S., Hinks A., Ollier W.E., et al. Association of protein kinase C alpha (PRKCA) gene with multiple sclerosis in a UK population. Brain 2004, 127:1717-1722.
15. Bergsteinsdottir K., Yang H.T., Pettersson U., Holmdahl R. Evidence for common autoimmune disease genes controlling onset, severity, and chronicity based on experimental models for multiple sclerosis and rheumatoid arthritis. J. Immunol. 2000, 164:1564-1568.
16. Blanco Y., Yague J., Graus F., Saiz A. No association of inducible nitric oxide synthase gene (NOS2A) to multiple sclerosis. J. Neurol. 2003, 250:598-600.
17. Bogdan C. Nitric oxide and the immune response. Nat. Immunol. 2001, 2:907-916.
18. Bruniquel D., Borie N., Triebel F. Genomic organization of the human LAG-3/CD4 locus. Immunogenetics 1997, 47:96-98.
19. Bruniquel D., Borie N., Hannier S., Triebel F. Regulation of expression of the human lymphocyte activation gene-3 (LAG-3) molecule, a ligand for MHC class II. Immunogenetics 1998, 48:116-124.
20. Bugeja M.J., Booth D.R., Bennetts B.H., Heard R.N., Burgner D., Stewart G.J. An investigation of NOS2A promoter polymorphisms in Australian multiple sclerosis patients. Eur. J. Hum. Genet. 2005, 13:815-822.
21. Burton P.R., Clayton D.G., Cardon L.R., Craddock N., Deloukas P., Duncanson A., et al. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat. Genet. 2007, 39:1329-1337.
22. Byun E., Caillier S.J., Montalban X., Villoslada P., Fernández O., Brassat D., et al. Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis. Arch. Neurol. 2008, 65:337-344.
23. Cardon L.R., Bell J.I. Association study designs for complex diseases. Nat. Rev. Genet. 2001, 2:91-99.
24. Comabella M., Craig D.W., Camina-Tato M., Morcillo C., Lopez C., Navarro A., et al. Identification of a novel risk locus for multiple sclerosis at 13q31.3 by a pooled genome-wide scan of 500,000 single nucleotide polymorphisms. PLoS ONE 2008, 3:e3490.
25. Compston A., Coles A. Multiple sclerosis. Lancet 2002, 359:1221-1231.
26. Consortium T.W.T.C.C. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007, 447:661-678.
27. Couturier N., Gourraud P.A., Cournu-Rebeix I., Gout C., Bucciarelli F., Edan G., et al. IFIH1-GCA-KCNH7 locus is not associated with genetic susceptibility to multiple sclerosis in French patients. Eur. J. Hum. Genet. 2009, 17:844-847.
28. Cox A.L., Thompson S.A., Jones J.L., Robertson V.H., Hale G., Waldmann H., et al. Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur. J. Immunol. 2005, 35:3332-3342.
29. Cunninghame Graham D.S., Manku H., Wagner S., Reid J., Timms K., Gutin A., et al. Association of IRF5 in UK SLE families identifies a variant involved in polyadenylation. Hum. Mol. Genet. 2007, 16:579-591.
30. Dardalhon V., Schubart A.S., Reddy J., Meyers J.H., Monney L., Sabatos C.A., et al. CD226 is specifically expressed on the surface of Th1 cells and regulates their expansion and effector functions. J. Immunol. 2005, 175:1558-1565.
31. De Jager P.L., Baecher-Allan C., Maier L.M., Arthur A.T., Ottoboni L., Barcellos L., et al. The role of the CD58 locus in multiple sclerosis. Proc. Natl. Acad. Sci. USA 2009, 106:5264-5269.
32. De Jager P.L., Jia X., Wang J., de Bakker P.I., Ottoboni L., Aggarwal N.T., et al. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat. Genet. 2009, 41:776-782.
33. Dean G. How many people in the world have multiple sclerosis?. Neuroepidemiology 1994, 13:1-7.
34. Deckert M., Kubar J., Bernard A. CD58 and CD59 molecules exhibit potentializing effects in T cell adhesion and activation. J. Immunol. 1992, 148:672-677.
35. Dietrich J.B. The adhesion molecule ICAM-1 and its regulation in relation with the blood-brain barrier. J. Neuroimmunol. 2002, 128:58-68.
36. D'Netto M.J., Ward H., Morrison K.M., Ramagopalan S.V., Dyment D.A., DeLuca G.C., et al. Risk alleles for multiple sclerosis in multiplex families. Neurology 2009, 72:1984-1988.
37. Douroudis K., Nemvalts V., Rajasalu T., Kisand K., Uibo R. The CD226 gene in susceptibility of type 1 diabetes. Tissue Antigens 2009, 74:417-419.
38. Dyment D.A., Willer C.J., Scott B., Armstrong H., Ligers A., Hillert J., et al. Genetic susceptibility to MS: a second stage analysis in Canadian MS families. Neurogenetics 2001, 3:145-151.
39. Ebers G.C., Sadovnick A.D., Risch N.J. A genetic basis for familial aggregation in multiple sclerosis. Canadian Collaborative Study Group. Nature 1995, 377:150-151.
40. Elorza A., Hyde B., Mikkola H.K., Collins S., Shirihai O.S. UCP2 modulates cell proliferation through the MAPK/ERK pathway during erythropoiesis and has no effect on heme biosynthesis. J. Biol. Chem. 2008, 283:30461-30470.
41. Encinas J.M., Manganas L., Enikolopov G. Nitric oxide and multiple sclerosis. Curr. Neurol. Neurosci. Rep. 2005, 5:232-238.
42. Enevold C., Oturai A.B., Sorensen P.S., Ryder L.P., Koch-Henriksen N., Bendtzen K. Multiple sclerosis and polymorphisms of innate pattern recognition receptors TLR1-10, NOD1-2, DDX58, and IFIH1. J. Neuroimmunol. 2009, 212:125-131.
43. Filmus J., Capurro M., Rast J. Glypicans. Genome Biol. 2008, 9:224.
44. Galimberti D., Fenoglio C., Clerici R., Comi C., De Riz M., Rottoli M., et al. E-selectin A561C and G98T polymorphisms influence susceptibility and course of multiple sclerosis. J. Neuroimmunol. 2005, 165:201-205.
45. Giedraitis V., He B., Hillert J. Mutation screening of the interferon-gamma gene as a candidate gene for multiple sclerosis. Eur. J. Immunogenet. 1999, 26:257-259.
46. Godde R., Rohde K., Becker C., Toliat M.R., Entz P., Suk A., et al. Association of the HLA region with multiple sclerosis as confirmed by a genome screen using >10,000 SNPs on DNA chips. J. Mol. Med. 2005, 83:486-494.
47. Goedde R., Sawcer S., Boehringer S., Miterski B., Sindern E., Haupts M., et al. A genome screen for linkage disequilibrium in HLA-DRB1*15-positive Germans with multiple sclerosis based on 4666 microsatellite markers. Hum. Genet. 2002, 111:270-277.
48. Goldstein D.B., Ahmadi K.R., Weale M.E., Wood N.W. Genome scans and candidate gene approaches in the study of common diseases and variable drug responses. Trends Genet. 2003, 19:615-622.
49. Goris A., Epplen C., Fiten P., Andersson M., Murru R., Sciacca F.L., et al. Analysis of an IFN-gamma gene (IFNG) polymorphism in multiple sclerosis in Europe: effect of population structure on association with disease. J. Interferon Cytokine Res. 1999, 19:1037-1046.
50. Govoni S., Racchi M., Bergamaschi S., Trabucchi M., Battaini F., Bianchetti A., et al. Defective protein kinase C alpha leads to impaired secretion of soluble beta-amyloid precursor protein from Alzheimer's disease fibroblasts. Ann. NY Acad. Sci. 1996, 777:332-337.
51. Graham R.R., Kyogoku C., Sigurdsson S., Vlasova I.A., Davies L.R., Baechler E.C., et al. Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus. Proc. Natl. Acad. Sci. USA 2007, 104:6758-6763.
52. Gregory S.G., Schmidt S., Seth P., Oksenberg J.R., Hart J., Prokop A., et al. Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis. Nat. Genet. 2007, 39:1083-1091.
53. Hafler D.A., Compston A., Sawcer S., Lander E.S., Daly M.J., De Jager P.L., et al. Risk alleles for multiple sclerosis identified by a genomewide study. N. Engl. J. Med. 2007, 357:851-862.
54. Hafler J.P., Maier L.M., Cooper J.D., Plagnol V., Hinks A., Simmonds M.J., et al. CD226 Gly307Ser association with multiple autoimmune diseases. Genes Immun. 2009, 10:5-10.
55. Hakonarson H., Grant S.F., Bradfield J.P., Marchand L., Kim C.E., Glessner J.T., et al. A genome-wide association study identifies KIAA0350 as a type 1 diabetes gene. Nature 2007, 448:591-594.
56. Hoppenbrouwers I.A., Aulchenko Y.S., Ebers G.C., Ramagopalan S.V., Oostra B.A., van Duijn C.M., et al. EVI5 is a risk gene for multiple sclerosis. Genes Immun. 2008, 9:334-337.
57. Hoppenbrouwers I.A., Aulchenko Y.S., Janssens A.C., Ramagopalan S.V., Broer L., Kayser M., et al. Replication of CD58 and CLEC16A as genome-wide significant risk genes for multiple sclerosis. J. Hum. Genet. 2009, 54:676-680.
58. Houston F.A., Wilson V., Jennings C.E., Owen C.J., Donaldson P., Perros P., et al. Role of the CD40 locus in Graves' disease. Thyroid 2004, 14:506-509.
59. Iglesias A.H., Camelo S., Hwang D., Villanueva R., Stephanopoulos G., Dangond F. Microarray detection of E2F pathway activation and other targets in multiple sclerosis peripheral blood mononuclear cells. J. Neuroimmunol. 2004, 150:163-177.
60. Kalman B., Albert R.H., Leist T.P. Genetics of multiple sclerosis: determinants of autoimmunity and neurodegeneration. Autoimmunity 2002, 35:225-234.
61. Kelly J.A., Kelley J.M., Kaufman K.M., Kilpatrick J., Bruner G.R., Merrill J.T., et al. Interferon regulatory factor-5 is genetically associated with systemic lupus erythematosus in African Americans. Genes Immun. 2008, 9:187-194.
62. Kretowski A., Wawrusiewicz N., Mironczuk K., Mysliwiec J., Kretowska M., Kinalska I. Intercellular adhesion molecule 1 gene polymorphisms in Graves' disease. J. Clin. Endocrinol. Metab. 2003, 88:4945-4949.
63. Kristjansdottir G., Sandling J.K., Bonetti A., Roos I.M., Milani L., Wang C., et al. Interferon regulatory factor 5 (IRF5) gene variants are associated with multiple sclerosis in three distinct populations. J. Med. Genet. 2008, 45:362-369.
64. Kruglyak L., Nickerson D.A. Variation is the spice of life. Nat. Genet. 2001, 27:234-236.
65. Leyva L., Fernandez O., Fedetz M., Blanco E., Fernandez V.E., Oliver B., et al. IFNAR1 and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-beta treatment response. J. Neuroimmunol. 2005, 163:165-171.
66. Li K.C., Palotie A., Yuan S., Bronnikov D., Chen D., Wei X., et al. Finding disease candidate genes by liquid association. Genome Biol. 2007, 8:R205.
67. Liao X., Buchberg A.M., Jenkins N.A., Copeland N.G. Evi-5, a common site of retroviral integration in AKXD T-cell lymphomas, maps near Gfi-1 on mouse chromosome 5. J. Virol. 1995, 69:7132-7137.
68. Lundmark F., Harbo H.F., Celius E.G., Saarela J., Datta P., Oturai A., et al. Association analysis of the LAG3 and CD4 genes in multiple sclerosis in two independent populations. J. Neuroimmunol. 2006, 180:193-198.
69. Lundmark F., Duvefelt K., Iacobaeus E., Kockum I., Wallstrom E., Khademi M., et al. Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis. Nat. Genet. 2007, 39:1108-1113.
70. Lyons D.A., Naylor S.G., Scholze A., Talbot W.S. Kif1b is essential for mRNA localization in oligodendrocytes and development of myelinated axons. Nat. Genet. 2009, 41:854-858.
71. Maalej A., Hamad M.B., Rebai A., Teixeira V.H., Bahloul Z., Marzouk S., et al. Association of IRF5 gene polymorphisms with rheumatoid arthritis in a Tunisian population. Scand. J. Rheumatol. 2008, 37:414-418.
72. Maier L.M., Lowe C.E., Cooper J., Downes K., Anderson D.E., Severson C., et al. IL2RA genetic heterogeneity in multiple sclerosis and type 1 diabetes susceptibility and soluble interleukin-2 receptor production. PLoS Genet. 2009, 5:e1000322.
73. Mandil R., Ashkenazi E., Blass M., Kronfeld I., Kazimirsky G., Rosenthal G., et al. Protein kinase Calpha and protein kinase Cdelta play opposite roles in the proliferation and apoptosis of glioma cells. Cancer Res. 2001, 61:4612-4619.
74. Manna I., Liguori M., Valentino P., Condino F., La Russa A., Clodomiro A., et al. Preliminary evidences of a NOS2A protective effect from relapsing-remitting multiple sclerosis. J. Neurol. Sci. 2008, 264:112-117.
75. Manolio T.A., Collins F.S., Cox N.J., Goldstein D.B., Hindorff L.A., Hunter D.J., et al. Finding the missing heritability of complex diseases. Nature 2009, 461:747-753.
76. Matsuzawa J., Sugimura K., Matsuda Y., Takazoe M., Ishizuka K., Mochizuki T., et al. Association between K469E allele of intercellular adhesion molecule 1 gene and inflammatory bowel disease in a Japanese population. Gut 2003, 52:75-78.
77. Mazzucchelli R., Durum S.K. Interleukin-7 receptor expression: intelligent design. Nat. Rev. Immunol. 2007, 7:144-154.
78. McDonald W.I., Compston A., Edan G., Goodkin D., Hartung H.P., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann. Neurol. 2001, 50:121-127.
79. McElroy J.P., Oksenberg J.R. Multiple sclerosis genetics. Curr. Top. Microbiol. Immunol. 2008, 318:45-72.
80. Miterski B., Jaeckel S., Epplen J.T., Pohlau D., Hardt C. The interferon gene cluster: a candidate region for MS predisposition? Multiple Sclerosis Study Group. Genes Immun. 1999, 1:37-44.
81. Modin H., Dai Y., Masterman T., Svejgaard A., Sorensen P.S., Oturai A., et al. No linkage or association of the nitric oxide synthase genes to multiple sclerosis. J. Neuroimmunol. 2001, 119:95-100.
82. Nakashima S. Protein kinase C alpha (PKC alpha): regulation and biological function. J. Biochem. 2002, 132:669-675.
83. Nejentsev S., Laaksonen M., Tienari P.J., Fernandez O., Cordell H., Ruutiainen J., et al. Intercellular adhesion molecule-1 K469E polymorphism: study of association with multiple sclerosis. Hum. Immunol. 2003, 64:345-349.
84. Niewold T.B., Kelly J.A., Flesch M.H., Espinoza L.R., Harley J.B., Crow M.K. Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients. Arthritis Rheum. 2008, 58:2481-2487.
85. Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S., Garber M., et al. DNA sequence and analysis of human chromosome 8. Nature 2006, 439:331-335.
86. Ohler B., Graf K., Bragg R., Lemons T., Coe R., Genain C., et al. Role of lipid interactions in autoimmune demyelination. Biochim. Biophys. Acta 2004, 1688:10-17.
87. Oksenberg J.R., Baranzini S.E., Barcellos L.F., Hauser S.L. Multiple sclerosis: genomic rewards. J. Neuroimmunol. 2001, 113:171-184.
88. Oksenberg J.R., Baranzini S.E., Sawcer S., Hauser S.L. The genetics of multiple sclerosis: SNPs to pathways to pathogenesis. Nat. Rev. Genet. 2008, 9:516-526.
89. Perera D., Stankovich J., Butzkueven H., Taylor B.V., Foote S.J., Kilpatrick T.J., et al. Fine mapping of multiple sclerosis susceptibility genes provides evidence of allelic heterogeneity at the IL2RA locus. J. Neuroimmunol. 2009, 211:105-109.
90. Pola R., Flex A., Gaetani E., Santoliquido A., Serricchio M., Pola P., et al. Intercellular adhesion molecule-1 K469E gene polymorphism and Alzheimer's disease. Neurobiol. Aging 2003, 24:385-387.
91. Ramagopalan S.V., Anderson C., Sadovnick A.D., Ebers G.C. Genomewide study of multiple sclerosis. N. Engl. J. Med. 2007, 357:2199-2200. (author reply 200-1).
92. Raychaudhuri S., Remmers E.F., Lee A.T., Hackett R., Guiducci C., Burtt N.P., et al. Common variants at CD40 and other loci confer risk of rheumatoid arthritis. Nat. Genet. 2008, 40:1216-1223.
93. Ricquier D., Bouillaud F. The uncoupling protein homologues: UCP1, UCP2, UCP3, StUCP and AtUCP. Biochem. J. 2000, 345:161-179.
94. Rubio J.P., Stankovich J., Field J., Tubridy N., Marriott M., Chapman C., et al. Replication of KIAA0350, IL2RA, RPL5 and CD58 as multiple sclerosis susceptibility genes in Australians. Genes Immun. 2008, 9:624-630.
95. Saarela J., Schoenberg Fejzo M., Chen D., Finnila S., Parkkonen M., Kuokkanen S., et al. Fine mapping of a multiple sclerosis locus to 2.5Mb on chromosome 17q22-q24. Hum. Mol. Genet. 2002, 11:2257-2267.
96. Saarela J., Kallio S.P., Chen D., Montpetit A., Jokiaho A., Choi E., et al. PRKCA and multiple sclerosis: association in two independent populations. PLoS Genet. 2006, 2:e42.
97. Sachidanandam R., Weissman D., Schmidt S.C., Kakol J.M., Stein L.D., Marth G., et al. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 2001, 409:928-933.
98. Sadovnick A.D., Baird P.A., Ward R.H. Multiple sclerosis: updated risks for relatives. Am. J. Med. Genet. 1988, 29:533-541.
99. Schmidt H., Williamson D., Ashley-Koch A. HLA-DR15 haplotype and multiple sclerosis: a HuGE review. Am. J. Epidemiol. 2007, 165:1097-1109.
100. Shibuya A., Campbell D., Hannum C., Yssel H., Franz-Bacon K., McClanahan T., et al. DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. Immunity 1996, 4:573-581.
101. Shimane K., Kochi Y., Yamada R., Okada Y., Suzuki A., Miyatake A., et al. A single nucleotide polymorphism in the IRF5 promoter region is associated with susceptibility to rheumatoid arthritis in the Japanese population. Ann. Rheum. Dis. 2009, 68:377-383.
102. Sigurdsson S., Padyukov L., Kurreeman F.A., Liljedahl U., Wiman A.C., Alfredsson L., et al. Association of a haplotype in the promoter region of the interferon regulatory factor 5 gene with rheumatoid arthritis. Arthritis Rheum. 2007, 56:2202-2210.
103. Sriram U., Barcellos L.F., Villoslada P., Rio J., Baranzini S.E., Caillier S., et al. Pharmacogenomic analysis of interferon receptor polymorphisms in multiple sclerosis. Genes Immun. 2003, 4:147-152.
104. Tabor H.K., Risch N.J., Myers R.M. Candidate-gene approaches for studying complex genetic traits: practical considerations. Nat. Rev. Genet. 2002, 3:391-397.
105. Tanaka C., Nishizuka Y. The protein kinase C family for neuronal signaling. Annu. Rev. Neurosci. 1994, 17:551-567.
106. Taniguchi T., Ogasawara K., Takaoka A., Tanaka N. IRF family of transcription factors as regulators of host defense. Annu. Rev. Immunol. 2001, 19:623-655.
107. Teutsch S.M., Booth D.R., Bennetts B.H., Heard R.N., Stewart G.J. Identification of 11 novel and common single nucleotide polymorphisms in the interleukin-7 receptor-alpha gene and their associations with multiple sclerosis. Eur. J. Hum. Genet. 2003, 11:509-515.
108. Todd J.A., Walker N.M., Cooper J.D., Smyth D.J., Downes K., Plagnol V., et al. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat. Genet. 2007, 39:857-864.
109. Tomer Y., Concepcion E., Greenberg D.A. A C/T single-nucleotide polymorphism in the region of the CD40 gene is associated with Graves' disease. Thyroid 2002, 12:1129-1135.
110. van Horssen J., Bö L., Dijkstra C.D., de Vries H.E. Extensive extracellular matrix depositions in active multiple sclerosis lesions. Neurobiol. Dis. 2006, 24(3):484-491. (Dec).
111. Van Rhijn I., van den Berg L.H., Bosboom W.M., Otten H.G., Logtenberg T. Expression of accessory molecules for T-cell activation in peripheral nerve of patients with CIDP and vasculitic neuropathy. Brain 2000, 123:2020-2029.
112. Van Vactor D., Wall D.P., Johnson K.G. Heparan sulfate proteoglycans and the emergence of neuronal connectivity. Curr. Opin. Neurobiol. 2006, 16:40-51.
113. Vandenbroeck K., Opdenakker G., Goris A., Murru R., Billiau A., Marrosu M.G. Interferon-gamma gene polymorphism-associated risk for multiple sclerosis in Sardinia. Ann. Neurol. 1998, 44:841-842.
114. Vogler S., Goedde R., Miterski B., Gold R., Kroner A., Koczan D., et al. Association of a common polymorphism in the promoter of UCP2 with susceptibility to multiple sclerosis. J. Mol. Med. 2005, 83:806-811.
115. Waldmann T.A. The interleukin-2 receptor. J. Biol. Chem. 1991, 266:2681-2684.
116. Weber F., Fontaine B., Cournu-Rebeix I., Kroner A., Knop M., Lutz S., et al. IL2RA and IL7RA genes confer susceptibility for multiple sclerosis in two independent European populations. Genes Immun. 2008, 9:259-263.
117. Wieczorek S., Hoffjan S., Chan A., Rey L., Harper L., Fricke H., et al. Novel association of the CD226 (DNAM-1) Gly307Ser polymorphism in Wegener's granulomatosis and confirmation for multiple sclerosis in German patients. Genes Immun. 2009, 10:591-595.
118. Workman C.J., Wang Y., El Kasmi K.C., Pardoll D.M., Murray P.J., Drake C.G., et al. LAG-3 regulates plasmacytoid dendritic cell homeostasis. J. Immunol. 2009, 182:1885-1891.
119. Yokoyama H., Tahara H., Emoto M., Fujiwara S., Araki T., Shinohara K., et al. The K469E polymorphism of the intercellular adhesion molecule-1 gene is associated with plasma fibrinogen level in type 2 diabetes. Metabolism 2005, 54:381-386.
120. Zhang Z., Duvefelt K., Svensson F., Masterman T., Jonasdottir G., Salter H., et al. Two genes encoding immune-regulatory molecules (LAG3 and IL7R) confer susceptibility to multiple sclerosis. Genes Immun. 2005, 6:145-152.
121. Zoledziewska M., Costa G., Pitzalis M., Cocco E., Melis C., Moi L., et al. Variation within the CLEC16A gene shows consistent disease association with both multiple sclerosis and type 1 diabetes in Sardinia. Genes Immun. 2009, 10:15-17.